MMED (NASDAQ:MMED) Coverage Initiated by Analysts at Evercore

Key Points

• Evercore initiated coverage on MMED with an "outperform" rating and a $20.00 price target, implying about a 39.37% upside from the prior close.
• Several other firms (Bank of America, Citigroup, Mizuho, BTIG) also initiated coverage or issued buy/outperform ratings, leaving a consensus of nine Buy and one Hold and a consensus target of $22.33.
• MMED opened at $14.35 on Tuesday with a one‑year range of $14.10–$20.48, and the company commercializes integrated diabetes‑management devices and solutions.

Equities research analysts at Evercore started coverage on shares of MMED (NASDAQ:MMED - Get Free Report) in a research note issued to investors on Tuesday. The firm set an "outperform" rating and a $20.00 price target on the stock. Evercore's price objective suggests a potential upside of 39.37% from the company's previous close.

Other analysts also recently issued research reports about the stock. Bank of America initiated coverage on shares of MMED in a report on Tuesday. They set a "buy" rating and a $27.00 price target on the stock. Wall Street Zen raised shares of MMED to a "hold" rating in a research report on Saturday, March 14th. Citigroup initiated coverage on MMED in a report on Tuesday. They set a "buy" rating and a $23.00 price target on the stock. Mizuho assumed coverage on MMED in a research report on Tuesday. They set an "outperform" rating and a $21.00 price objective for the company. Finally, BTIG Research started coverage on MMED in a research note on Tuesday. They set a "buy" rating and a $25.00 price target for the company. Nine research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $22.33.

MMED Stock Performance

NASDAQ MMED opened at $14.35 on Tuesday. MMED has a one year low of $14.10 and a one year high of $20.48.

MMED Company Profile

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.